MAOB and Parkinson disease: The efficacy of levodopa has been shown to exceed that of other comparable PD treatment modalities, including dopamine agonists, anticholinergics, monoamine oxidase-B (MAO-B) inhibitors, and amantadine, in mobility outcomes and quality-of-life measures.